

BIODEGRADABLE DRUG DELIVERY VASCULAR STENT

Patent Number: WO9306792

Publication date: 1993-04-15

Inventor(s): PALME II DONALD F (US); WANG LIXIAO (US); BUSCEMI PAUL J (US); DOYLE ERIN S (US); STEJSKAL ELIZABETH A (US)

Applicant(s): SCIMED LIFE SYSTEMS INC (US)

Requested Patent: WO9306792 *D4*

Application Number: WO1992US08463 19921002

Priority Number (s): US19910771655 19911004; US19920944069 19920911

IPC Classification: A61F2/06

EC Classification: A61L31/14K, A61L31/16, A61F2/06S, A61F2/06S6C

Equivalents:

Cited Documents: US5147400; US4877030; US5078736

Abstract

A biodegradable stent (10, 50) for insertion into a lumen (13) of a vessel (12) of a living being includes a generally tubular biodegradable main body (11, 58). The main body (11, 58) includes an exterior surface (56) for contacting the vessel when the main body is placed in the living being and an interior surface (54) contacting a fluid passing through the lumen of the vessel. The tubular main body (11, 58) is made of an array of individual biodegradable materials having individual rates of degradation. The individual biodegradable materials incorporate a drug and release the drug into the lumen (13) of the vessel (12) at a rate controlled by the rate of degradation of the biodegradable materials.

Data supplied from the esp@cenet database - I2

BEST AVAILABLE COPY

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61F 2/06	A1	(11) International Publication Number: WO 93/06792 (43) International Publication Date: 15 April 1993 (15.04.93)
(21) International Application Number: PCT/US92/08463 (22) International Filing Date: 2 October 1992 (02.10.92)		(74) Agents: SAWICKI, Z., Peter et al.; Kinney & Lange, 625 Fourth Avenue South, Suite 1500, Minneapolis, MN 55415-1659 (US).
(30) Priority data: 07/771,655 4 October 1991 (04.10.91) US 07/944,069 11 September 1992 (11.09.92) US		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).
(71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US]; 6655 Wedgwood Road, Maple Grove, MN 55369-7503 (US).		Published <i>With international search report.</i>
(72) Inventors: BUSCEMI, Paul, J. ; 2310 Tamarack Drive, Long Lake, MN 55369 (US). STEJSKAL, Elizabeth, A. ; 1311 Grand Avenue, Apartment B, St. Paul, MN 55105 (US). PALME, Donald, F. III ; 13820 Balsam Lane, Dayton, MN 55327 (US). WANG, Lixiao ; 1184 Fifield Avenue, St. Paul, MN 55108 (US). DOYLE, Erin, S. ; 3025 - 30th Avenue South, Apartment 103, Minneapolis, MN 55406 (US).		

(54) Title: BIODEGRADABLE DRUG DELIVERY VASCULAR STENT



(57) Abstract

A biodegradable stent (10, 50) for insertion into a lumen (13) of a vessel (12) of a living being includes a generally tubular biodegradable main-body (11, 58). The main body (11, 58) includes an exterior surface (56) for contacting the vessel when the main body is placed in the living being and an interior surface (54) contacting a fluid passing through the lumen of the vessel. The tubular main body (11, 58) is made of an array of individual biodegradable materials having individual rates of degradation. The individual biodegradable materials incorporate a drug and release the drug into the lumen (13) of the vessel (12) at a rate controlled by the rate of degradation of the biodegradable materials.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republie of Korea	SE	Sweden
CH	Switzerland	LJ	Liechteinstein	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Sri Lanka	SN	Senegal
CM	Cameroon	LU	Luxembourg	SU	Soviet Union
CS	Czechoslovakia	MC	Monaco	TD	Chad
CZ	Czech Republic	MG	Madagascar	TG	Togo
DE	Germany	ML	Malta	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

-1-

BIODEGRADABLE DRUG DELIVERY VASCULAR STENT

This Application is a Continuation-In-Part of U.S. Application No. 07/771,655, filed October 4, 1991.

BACKGROUND OF THE INVENTION

5 This invention relates to a device for providing mechanical support to a vessel lumen of a living being.

10 A variety of medical situations requires the use of a mechanism to expand and support a constricted vessel and to maintain an open passageway through the vessel. A few examples of such situations following angioplasty include holding a dissection in place, preventing closure during spasm, and preventing acute closure due to thrombosis. In these situations, 15 devices, commonly known as stents, are useful to prevent stenosis of a dilated vessel, or to eliminate the danger of occlusion caused by "flaps" resulting from intimal tears that may be associated with angioplasty, or to hold two ends of a vessel in place.

20 Stents have been made using materials of varied composition and conformation. McGreevy et al. U.S. Patents 4,690,684 and 4,770,176, describe a meltable stent that is inserted into the interior of the ends of a blood vessel during anastomosis. Anastomosis refers to the surgical or physical connection of two 25 tubular structures, such as veins or arteries. The stent is made of blood plasma, which is biologically compatible with the living being and which melts rapidly in response to heat.

30 The Fischell et al. U.S. Patent 4,768,507, describes an intravascular stent which is an unrestrained coil spring having an outside diameter of 2 to 12 millimeters and a length of 5 to 25 millimeters.

-2-

The materials of construction are stainless steel, and a titanium alloy. Decreased thrombogenicity is achievable by coating the outside of the coil with a non-thrombogenic material such as ULTI carbon.

5 The Leeven et al. U.S. Patent 4,820,298, describes a stent having a flexible tubular body made from a thermal plastic to the form of a helix. Polyester and polycarbonate copolymers are selected as particularly desirable materials.

10 The Wolff et al. U.S. Patent 4,830,003, describes a stent made from wires formed into a cylinder. The wires are made of a biocompatible metal. Biocompatible metals include 300 series stainless steels such as 316 LSS, as well as platinum and 15 platinum-iridium alloys, cobalt-chromium alloys such as MP35N, and unalloyed titanium.

20 The Wiktor U.S. Patent 4,886,062, describes a stent made from low memory metal such as a copper alloy, titanium, or gold. The stent is preformed into a two-dimensional zig-zag form creating a flat expandable band.

25 The Gianturco U.S. Patent 4,907,336, describes a wire stent having a cylindrical shape that results from an expandable serpentine configuration. Malleable materials of construction are preferably included from the group of annealed stainless steels, tungsten and platinum.

30 Goldberg et al., Canadian Application 2,025,626, describe a bio-degradable infusion stent used to treat ureteral obstructions. The application describes an extruded material of construction made of epsilon-caprolactone (15-25% w/w of terpolymer composition); glycoside (5-50% w/w) and L(-)lactide

-3-

(45-85% w/w). This material was described as having a minimum tensile strength of at least 500 pounds per square inch, preferably 650 psi; elongation of greater than 10%, preferably greater than 100%; and Shore A 5 hardness equal to 50-100%, preferably 75-95%. The Goldberg et al. patent application describes a method for incorporating radiopaque materials such as barium sulfate into the polymer in amounts ranging from 5-30%. The mechanism of biodegradation is described as 10 hydrolysis resulting in degradable products excreted in urine or reabsorbed into tissues. The duration of functional life of the stent is estimated at about 3-7 weeks.

The Wilcoff U.S. Patent 4,990,155, describes 15 a plastic stent having an inherently expandable coil conformation. The "inherency" results from an elastic memory conferred by electron beam radiation imparting cross-linkages that provide an inherent tendency to return to a given diameter after any distortion. 20 Materials of construction include high density polyethylene. Optionally, this material is compounded with an anti-coagulant and/or an x-ray opaque material such as bismuth-sub-carbonate.

The Shockley et al. U.S. Patent 4,994,033, 25 describes a drug delivery dilatation catheter having three flexible, plastic tubes concentrically arranged relative to each other. The outermost sleeve of this catheter contains microholes for drug delivery. These microholes are made with a laser beam. Drugs that can 30 be delivered by this system include aspirin, persantin, heparin, and prostaglandins. Drugs are delivered when externally applied pressure causes the innermost sleeve

-4-

to balloon out. The drug is then forced through the microholes to spray and to treat a lesion.

Sigwart, Canadian Patent Application
2,008,312, describes a stent made from a malleable flat
sheet having a reticulated pattern. The reticulated
pattern includes non-deformable squares or diamonds.
The stent is made by rolling the sheet and locking the
sheet into a spiral having a small diameter. The sheet
is locked into a spiral by a tie interwoven into the
reticulated pattern. Once inserted into the lumen of a
vessel, the spiral is expanded and held in place by
flaps integrated into the outer body of the stent.

15 The Kawai et al. U.S. patent 4,950,258, describes a biodegradable molded product having a first shape. The molded product is deformed at an elevated deforming temperature to form a second shape. The product is then cooled. When the product is reheated to a prescribed temperature, the product recovers the first shape.

20 The Brandley et al. U.S. patent 5,032,679, describes a glycosaminoglycoside (GAG) composition made of tetrasaccharide units derived from heparin/heparin sulfate. The composition has use in preventing proliferation of smooth muscle cells.

25 The Mares et al. U.S. patent 5,061,281, describes a medical device made from a resorbable homopolymer derived from the polymerization of an alpha-
30 hydroxy carboxylic acid. The resorbable homopolymer has an average molecular weight of from 234,000 to 320,000 as measured by gel permeation chromatography.

The Sinclair U.S. patent 4,057,537, describes a copolymer prepared by copolymerizing an optically active lactide and epsilon caprolactone in the presence

-5-

of a tin ester of carboxylic acid. The copolymer is biodegradable.

The Seilor, Jr. et al. U.S. patent 4,550,447, describes a porous tube for use in a lumen of a vessel.

5 The porous tube includes ribs for ingrowth. Pores of the porous tube promote tissue ingrowth.

The Spears U.S. patent 4,799,479, describes the use of a heated balloon to fuse tissue of a blood vessel. The balloon is heated by a laser.

10 The Spears U.S. patent 5,092,841, describes the use of a heated balloon to bond a bioprotective material to an arterial wall. The bioprotective material permeates into fissures and vessels of the arterial wall.

15 The Sawyer U.S. patent 5,108,417, describes a stent made from a helically shaped titanium or aluminum strip having an airfoil on an interior surface. The airfoil increases blood flow velocity through the stent.

20 The Hillstead U.S. patent 5,116,318, describes a dilation balloon assembly that includes an expandable sleeve. The expandable sleeve, positioned around a balloon of the assembly, eliminates a formation of "blade-like" edges on the balloon.

25 The Savin et al. U.S. patent 4,950,227, describes a stent delivery system that includes a pair of expandable cuffs that are positioned over opposing ends of a stent. The stent is positioned around a balloon attached to a catheter. The cuffs are positioned around the catheter so that when the balloon expands, expanding the stent, the stent is released from the cuffs.

30 Cox et al. in Coron. Artery Dis. 3 at 3 (1992) describe a tantalum stent that is balloon expandable and

-6-

is coated with a cellulose ester. The cellulose ester includes methotrexate, heparin or a combination of both drugs.

5 The stents mentioned do not remedy all problems relating to stents. In particular, some uses require stents to safely degrade within the bloodstream of an artery or vein over a period of weeks to months. Such stents must meet particular criteria. For instance, such stents must be compatible with 10 surrounding tissue in the vein or artery as well as with blood flowing through the vein or artery. Degradation products must be prevented from forming emboli.

15 Stents should also optimize flow through a vein or artery. Additionally, there is a need for stents which deliver agents or drugs to blood passing through the vein or artery that are generally beneficial to the recipient. Also desired are stents which can deliver drugs or biologically active agents at a controlled rate to blood passing through the vessel 20 lumen as well as to the vessel wall.

SUMMARY OF THE INVENTION

25 The present invention includes a stent for insertion into a lumen of a vessel in a living being. The stent includes a generally tubular main body having an exterior surface for contacting the lumen when the stent is placed in a living being and an interior surface contacting a fluid passing through the lumen of the vessel. The tubular main body is made from an array of individual biodegradable materials having individual 30 rates of degradation. The individual biodegradable materials incorporate a drug and release the drug into the lumen of the vessel at rates controlled by the rates of degradation of the biodegradable materials.

-7-

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an enlarged perspective view of one embodiment of the stent of the present invention.

5 Figure 2 is a cross-sectional view of the stent embodiment.

Figure 3 is an overview of one embodiment of opposing edges bounding a slot extending lengthwise along the main body of the stent of the present invention.

10 Figure 4 is an enlarged perspective view of a coiled stent embodiment of the present invention.

Figure 5 is a cross-sectional view of a main body of the coiled stent embodiment of the present invention.

15

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20 The present invention includes a biodegradable stent generally illustrated at 10 in Figure 1. The stent 10 releases drugs into a tubular vessel 12 having a lumen 13 in a living being. The rate of drug release is controlled by the rate of degradation of the biodegradable materials. The stent 10 also provides mechanical support to a tubular vessel 12 in a living being. The stent strengthens an area of the vessel that is in contact with the stent 10.

25 The stent 10 includes a generally tubular main body 11 and a plurality of fibers 18 disposed around the main body 11. A plurality of apertures 14 extend through the stent 10. The stent 10 also includes a slot 26 extending the length of the stent.

30 The tubular main body 11 includes an outer surface 16 and inner surface 22. The outer surface 16 of the main body 11 faces an inner surface wall 24 of

-8-

the vessel 12. The inner surface 22 of the stent 10 faces a stream flowing through the lumen 13 as shown in cross section in Figure 2. The stent of the present invention may range from 1 millimeter in diameter to 50 millimeters in diameter and from 1 millimeter in length to 50 millimeters in length. The size of the stent is dictated by the lumen of the vessel to which the stent is placed. The tubular main body suitably has a length of up to approximately 5 centimeters.

The plurality of fibers 18 disposed around the main body 11 contacts the outer surface 16 of the main body. In one preferred embodiment, the fibers are arranged concentrically around the main body, encircling the outer surface 16 in an annular alignment. The annular alignment is ordered so that individual fibers are separated by approximately the same distance. Alternatively, the fibers are arranged in annular pairs or triplets. In another embodiment, the plurality of fibers abut each other in annular alignment.

In another embodiment, the plurality of fibers 18 of the outer surface are braided. Braided fibers are also arranged in annular alignment around the main body of the stent 10. In one other embodiment, the fibers are woven. Woven fibers increase the stretch and flexibility of the stent compared to fibers which are not woven. Solid fibers, hollow fibers, or a combination thereof can be used for any of the embodiments described above.

The plurality of fibers 18 of the main body 11 can be formed by techniques well known in the art. These techniques include melt, wet and dry spinning. High molecular weight polymers having a range of 200,000 to 3,000,000 daltons are preferred for successful fiber

-9-

production. One example of a biodegradable material meeting this criterion for fiber manufacture is poly-L-lactide.

5 The fibers generally undergo further orientation in the extruded direction. One technique for orienting the fibers is to stretch the fibers at a temperature range of 50° to 150°C.

Desirably, the plurality of fibers 18 disposed around the main body 11 of the stent 10 have an outer 10 diameter not exceeding approximately 0.2 millimeters. In the case of hollow fibers, the wall thicknesses should be within the approximate range of 25 to 100 microns. Preferably, the fibers should have a tensile strength in a range of 4,000 to 500,000 pounds per 15 square inch and have a modulus of 200,000 to 2,000,000 pounds per square inch.

In one embodiment, the main body includes a film that is preferably combined with the plurality of fibers disposed around the main body 11. The film 20 combined with the plurality of fibers defines the outer surface 16 of the main body. The plurality of fibers can be combined with the film using any number of conventional methods. In one conventional method, solvation sealing, the steps of heat pressing and 25 extrusion molding combine the film and fiber production into one step for the orientation of the polymer materials. Additional methods include solvent sealing of the fibers to the film or heat melting processes for the annealing of the multiple layers. By the solvation 30 sealing method, fibers and film are combined to form the outer surface into a single biodegradable material matrix.

-10-

5 Preferably, the main body 11 of the stent 10 includes a film 32, covering the inner surface 22. The film 32 of the inner surface 22 is formed by conventional methods such as heat or pressure extrusion or solution casting.

10 Additionally, the present invention includes an embodiment where the inner surface 22 and the outer surface 16 of the main body 11 are separated by at least one interior film layer. The interior film layer is integrated into the main body by multiple casting with the inner and outer surfaces. The present invention further includes a main body having more than one biodegradable interior film layer. Desirably, the thickness of the main body does not exceed approximately 15 0.25 millimeters.

20 The plurality of apertures of the present invention is preferably ordered around the main body to form rows of apertures. Figure 1 illustrates two rows of apertures, the length of each row extending the length of the tubular main body. In an alternative embodiment, the plurality of apertures are ordered to form one row having a length extending the length of the tubular main body. The apertures within the one row are bounded by edges 28 and 30 bordering the slot 26. In 25 one other embodiment, the plurality of apertures are ordered to form a row extending less than the length of the main body of the stent. In another embodiment, the plurality of apertures are not ordered but are located randomly over the main body of the stent.

30 Suitable shapes for the individual apertures include both asymmetrical and symmetrical shapes such as ovals, circles, or rectangles. Also, apertures may be

-11-

made in a variety of sizes. The apertures can be formed by any conventional means such as stamping.

5 The slot 26 extends the length of the stent and is defined by opposing edges 28 and 30 of the main body as illustrated in Figure 3. In a preferred embodiment, the fibers 18 are oriented fibers and are fixed to the outer surface 16 of the main body 11. When the slot 26 is formed, the oriented fibers 18 provide a spring force in an outward substantially radial 10 direction. The outward spring force increases the effective diameter of the main body while the slot permits compression or reduction of the effective diameter. Once formed, the stent is normally at its effective maximum diameter and the slot is at its 15 widest.

20 In use, the stent is positioned at the inner surface wall 24 of the vessel 12 by radially compressing the stent to a tubular diameter less than the diameter of the vessel 12 and moving the stent to a desired site within the vessel. The stent is secured by releasing the stent from compression so that the stent can radially spring out to abut against the inner surface 25 wall 22 of the vessel 12.

25 In the most preferred embodiment, the biodegradable stent of the present invention is made of biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. It is important to 30 the present invention that the plurality of apertures 14 in the main body 11 of the stent promote the successful biodegradation of the stent 10. Optimally, the plurality of apertures 14 permits epithelial cells to

-12-

grow on the stent 10. It is believed that the epithelial cell growth will encapsulate particles of the stent during biodegradation that would otherwise come loose and form emboli in the bloodstream.

5 Suitable biodegradable materials for the main body 11 of the stent 10 of the present invention include polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, hylauric acid, adhesive proteins, 10 co-polymers of these materials as well as composites and combinations thereof and combinations of other biodegradable polymers. Biodegradable glass or bioactive glass is also a suitable biodegradable material for use in the present invention. Preferably 15 the materials have been approved by the U.S. Food and Drug Administration.

20 The present invention includes a biodegradable stent incorporating a variety of biodegradable materials within it. For instance, in one embodiment, the film and fibers covering the inner surface 22 of the main body 11 of the biodegradable stent is made of either polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, copolymers of these materials as well 25 as composites thereof and combinations of other biodegradable polymers. The film covering the outer surface 16 along with the plurality of fibers 18 are made of either collagen, hylauric acid, adhesive proteins, copolymers of these materials as well as composites and combinations thereof. The present 30 invention includes an embodiment where fibers are made from more than one biodegradable material. Also, the present invention includes an embodiment where the film

-13-

is made from a biodegradable material different from the fibers.

One other embodiment of the biodegradable stent of the present invention includes a biodegradable 5 coiled stent, illustrated at 50 in Figure 4. The coiled stent 50 includes a main body strip 58 made of a biodegradable material, having an exterior surface 56, a cambered interior surface 54, a leading end 66 and a trailing end 68 opposing the leading end. The 10 biodegradable coiled stent 50 is most preferably helically coiled.

The biodegradable coiled stent 50 most preferably has a length-to-diameter ratio of at least about 1-to-2. The length-to-diameter ratio of at least 15 about 1-to-2 prevents the coiled stent from flipping out of position and tumbling through the lumen. In one embodiment, the coiled stent 50 has a length of at least about 3 mm. The main body strip 58 of the coiled stent 50 is preferably made from a strip of biodegradable 20 material having a width of about 2 millimeters.

The main body strip 58 is most preferably formed into a plurality of individual, integral coils as shown at 62 and 64 to make the coiled stent 50. The individual, integral coils 62 and 64 are spaced to 25 permit epithelial cells to grow on the coiled stent 50.

The exterior surface 56 of the main body strip 58 faces the lumen of the vessel. The exterior surface 56 is preferably textured by a plurality of pores (not shown). The plurality of pores are sized and positioned 30 in order to promote adhesion of the coiled stent 50 to the vessel wall. Specifically, the pores are sized to promote ingrowth of cells of the vessel wall onto the exterior surface 56. In one embodiment, the pores have

-14-

a diameter within a range of about 0.1 to 30.0 microns and an apparent density of about 10 to 70% of a non-porous material density.

5 The cambered interior surface 54 of the main body strip 58 contacts the fluid stream passing through the lumen of the vessel once the strip 58 has been coiled and inserted into the lumen. The cambered interior surface 54 is preferably symmetrical and smooth. The cambered interior surface 54 of the main body strip 58 includes a camber 60, most preferably having a maximum angle of curvature within a range of about 10 to 20 degrees. The camber 60 extends outwardly, into the fluid stream, in a convex fashion as shown in cross-section in Figure 5.

15 The leading end 66 of the main body strip 58 faces a direction of flow of fluid passing through the vessel lumen. The trailing end 68 opposes the leading end 66. Most preferably, the main body strip 58 has a thickness that is substantially the same at the leading end 66 as at the trailing end 68. In one preferred thickness profile embodiment for the main body strip 58 illustrated in Figure 5, the main body 58 has a minimum thickness at the leading end 66 and trailing end 68. Preferably, the thickness is symmetrically tapered to approach zero microns at each of the leading end 66 and trailing end 68.

20 The cambered interior surface 54, the leading end 66 and the trailing end 68 together prevent the formation of eddys, formed in a wake that is made when a fluid such as blood passes through each coil 62 and 64 of the coiled stent 50. The cambered interior surface 54, leading end 66 and trailing end 68 are also believed 30 to reduce the wake size for each coil 62 and 64 and are

-15-

believed to reduce pressure drag on each coil 62 and 64. The cambered interior surface 54, the leading end 66 and the trailing end 68 of the stent are believed to prevent the formation of eddys for stents made of materials 5 other than biodegradable materials. Thus, the present invention includes embodiments having a leading end 66, cambered interior surface 54 and trailing end 68 made of biocompatible materials that are not biodegradable but will produce the desired reduction in pressure drag.

10 To install in a lumen of a vessel, the coiled stent 50 is positioned at a wall (not shown) of the lumen by radially compressing the stent to a tubular diameter less than the diameter of the vessel and moving the stent 50 to a desired site within the vessel. The 15 stent 50 is secured by releasing the stent 50 from compression so that the stent 50 can radially spring out to abut against the wall of the vessel.

20 In one installation embodiment, the biodegradable coiled stent 50 includes a plurality of microcapsules that are dispersed in the biodegradable material. The microcapsules contain a material that induces crosslinking of the biodegradable material. The biodegradable stent including the plurality of 25 microcapsules is further expanded while in the lumen and is heated with a heated balloon and is cooled while the stent is in an expanded position.

20 The balloon contacts the cambered interior surface 54 of the coiled stent 50 and heats the stent with a magnitude of thermal energy that will cause the microcapsules to burst and release the material that induces crosslinking. Crosslinking the biodegradable material imparts a strength to the stent sufficient to hold open the lumen.

-16-

The thermal energy will not be of a magnitude great enough to change surrounding lumen tissue. In particular, the thermal energy will not either fuse lumen tissue or cause a bonding of tissue with the 5 stent. To the contrary, it is important to the coiled stent embodiment 50 of the present invention that thermal energy from the balloon not change living lumen tissue.

10 The thermal energy includes energy derived from heated fluids, electromagnetic energy and ultrasonic energy. In one embodiment, the thermal energy heats the biodegradable material of the stent to a temperature above a glass transition temperature of the biodegradable material but below a melting point of 15 the material.

20 In one other embodiment, the thermal energy heats the biodegradable material of the stent to a first temperature that is lower than the glass transition temperature of the biodegradable material. Then, the stent is heated to a second temperature above the glass 25 transition temperature of the biodegradable material.

Once the biodegradable material of the stent is heated above its glass transition temperature, the material softens. The balloon is then expanded. The 30 expanded balloon radially enlarges the diameter of the stent. The stent, having an enlarged diameter, is then allowed to cool in an expanded position and the balloon is removed. In one other embodiment, the stent is expanded by the balloon before being heated to a temperature above the glass transition temperature of its biodegradable material.

The present invention includes one other installation embodiment for a biodegradable stent having

-17-

a biodegradable tubular main body. The biodegradable tubular main body is made of a deformable, biodegradable material that overlays a balloon of a catheter. When the deformable, biodegradable material overlays the 5 balloon, the material assumes a shape of the tubular main body. Acceptable tubular shapes include a slotted tubular shape as shown in Figure 1 and a helically coiled shape as shown in Figure 4. The deformable, biodegradable material is preferably coated with a 10 biodegradable, biocompatible film that adheres the biodegradable material to the balloon.

In one embodiment, the biodegradable film forms a water soluble, viscous interface between the tubular main body and the balloon when wetted. The 15 film gradually dissolves in a water component of blood while passing through the lumen. The biodegradable film dissolves at a rate that permits adherence of the tubular main body to the balloon by the film during passage of the stent and balloon through the lumen and 20 during an expansion of the balloon and the tubular main body. However, the film is dissolved once the stent is expanded to a degree that permits the stent to be separated from the balloon. The water soluble film is acceptably made from materials that include high 25 molecular weight polyethylene glycol, high molecular weight carbohydrates and high molecular weight polyvinylpyrrolidone. The water soluble film also acceptably includes an antithrombic drug to aid in the reduction of thrombosis.

30 In another embodiment, the biodegradable, biocompatible film is melttable upon application of thermal energy. The melttable film is acceptably made from ionic, crosslinked polymers that include

-18-

combinations of anionic carbohydrates with polycations.

The balloon of the catheter, having the biodegradable tubular main body adhered, is positioned within the lumen at a site where the tubular main body 5 of the stent is to be installed. Once positioned, the balloon is expanded, radially expanding the diameter of the tubular main body. The biodegradable tubular main body is then heated to a temperature above the glass transition temperature and below a melting temperature 10 of the biodegradable material, softening the biodegradable material of the tubular main body. Heating the tubular main body also melts the meltable film coating of the tubular main body, permitting release of the tubular main body from the balloon.

15 The source of energy for heating the tubular main body is suitably derived from heated fluids, electromagnetic energy and ultrasonic energy. In one embodiment, a fluid contained in the balloon is heated by a heating element also contained in the balloon.

20 The tubular main body is subsequently allowed to cool. Once the main body is cooled, the balloon is deflated and removed from the lumen. The cooled and strengthened biodegradable stent remains in the lumen.

25 The present invention also includes embodiments where the deformable, biodegradable material of the tubular main body is strengthened by an application of mechanical energy. In one embodiment, the mechanical energy is applied to the tubular main body to reorient molecules of the biodegradable material 30 of the stent. The mechanical energy is applied at a temperature below a glass transition temperature of the material. The mechanical energy is of a magnitude below an elastic limit of the biodegradable material.

In another embodiment using mechanical energy, the biodegradable material of the tubular main body includes the plurality of microcapsules. The microcapsules include materials that induce crosslinking 5 in the biodegradable material. The mechanical energy is applied to the tubular main body in order to burst the microcapsules. Once burst, the microcapsules release the materials that induce crosslinking of the biodegradable material. The biodegradable material is 10 then crosslinked and is strengthened.

The mechanical energy is applied by inflating the balloon to which the tubular main body is adhered. Inflating the balloon radially expands and stretches the deformable, biodegradable material of the tubular main 15 body. The stretching is of a magnitude to reorient molecules of one stent embodiment. The stretching is also of a magnitude to burst microcapsules contained in the biodegradable material of the second embodiment.

In one embodiment of the biodegradable coiled 20 stent 50, the main body 58 is made from a single individual biodegradable material such as polylactic acid (pla). Preferably, the pla has a low degree of polymerization (dp).

In one other embodiment, the main body 58 is 25 made from a plurality of individual, biodegradable materials arranged in layers. Each of the individual, biodegradable layers has distinct physical and chemical properties.

In one layered embodiment of the coiled stent 30 50, an inner layer contacting the fluid passing through the vessel lumen, is made of either polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone,

-20-

5 copolymers of these materials as well as composites thereof and combinations of other biodegradable polymers. An outer layer, contacting a wall of the adhesive proteins, copolymers of these materials as well as composites and combinations thereof.

10 One advantage of using the variety of biodegradable materials within the tubular main body embodiment of Figure 1 and the coiled stent embodiment 50 of Figure 4 is control of degradation. Biodegradable materials degrade at different rates, ranging from weeks to several years. Consequently, the presence of different biodegradable materials in the stent permits the stent to degrade in a predictable, orchestrated 15 fashion.

20 The stent embodiments of the present invention further include incorporation of a drug or drugs or other biologically active materials. The drugs are contained within the biodegradable materials of which the stent is composed. As the stent biodegrades, drugs are administered to the surrounding tissue or to the 25 blood stream. Thus, the rate of drug release is controlled by the rate of degradation of the biodegradable materials. A material that degrades rapidly will release the drug faster than a material that degrades slowly.

30 Additionally, the rate of drug release can either accelerate or slow down the rate of degradation of the biodegradable material. Thus, the rate of release of a drug acts as a control quantity for the rate of degradation. For instance, one coiled stent embodiment could include a coiled main body made from a strip having four layers. A first layer, contacting the

-21-

vessel wall, could incorporate the drug, fibronectin. A second layer contacting the first layer, could incorporate the drug fibronectin at a lower concentration than the first layer. A third layer 5 contacting the second layer could incorporate fibronectin at a lower concentration than either the first or the second layer. A fourth layer could contact the fluid passing through the lumen and could incorporate the drug, heparin.

10 The drug fibronectin accelerates growth of cells surrounding the stent. The accelerated growth of cells accelerates resorption reactions of the first layer of the stent. A reduced fibronectin concentration in the second and third layers slows down the resorption 15 reactions so that the degradation of the first three layers will proceed at a cumulative rate that is compatible with the degradation of the fourth layer.

Drugs are incorporated into the biodegradable stent using techniques known in the art. The techniques 20 include simple mixing or solubilizing with polymer solutions, dispersing into the biodegradable polymer during the extrusion of melt spinning process, or coating onto an already formed film or fiber. In one embodiment, hollow fibers, which contain 25 anti-thrombogenic drugs, are arranged in a parallel concentric configuration with solid fibers for added support for use on the outer surface 16 of the main body 11 of the stent 10.

Further, drugs can be incorporated into the 30 film of both the inner and outer surfaces by using methods such as melting or solvation. If an interior film layer is present within the main body as well, the interior layer and inner and outer surfaces are then

-21-

vessel wall, could incorporate the drug, fibronectin. A second layer contacting the first layer, could incorporate the drug fibronectin at a lower concentration than the first layer. A third layer 5 contacting the second layer could incorporate fibronectin at a lower concentration than either the first or the second layer. A fourth layer could contact the fluid passing through the lumen and could incorporate the drug, heparin.

10 The drug fibronectin accelerates growth of cells surrounding the stent. The accelerated growth of cells accelerates resorption reactions of the first layer of the stent. A reduced fibronectin concentration in the second and third layers slows down the resorption 15 reactions so that the degradation of the first three layers will proceed at a cumulative rate that is compatible with the degradation of the fourth layer.

Drugs are incorporated into the biodegradable stent using techniques known in the art. The techniques 20 include simple mixing or solubilizing with polymer solutions, dispersing into the biodegradable polymer during the extrusion of melt spinning process, or coating onto an already formed film or fiber. In one embodiment, hollow fibers, which contain 25 anti-thrombogenic drugs, are arranged in a parallel concentric configuration with solid fibers for added support for use on the outer surface 16 of the main body 11 of the stent 10.

Further, drugs can be incorporated into the 30 film of both the inner and outer surfaces by using methods such as melting or solvation. If an interior film layer is present within the main body as well, the interior layer and inner and outer surfaces are then

-22-

combined with each other such as by mechanically pressing one layer to the other layer in a process augmented by heat or solvation adhesives. In another embodiment, drugs or biologically active agents are 5 incorporated into the film layer and surfaces by entrapment between the layers and surfaces of biodegradable material sandwiched together, thereby further promoting release of the drugs or agents at different rates.

10 The drugs or other biologically active materials incorporated into the stent of the present invention perform a variety of functions. The functions include but are not limited to an anti-clotting or anti-platelet function; and preventing smooth muscle 15 cell growth on the inner surface wall of the vessel. The drugs include but are not limited to drugs that inhibit or control the formation of thrombus or thrombolytics such as heparin or heparin fragments, aspirin, coumadin, tissue plasminogen activator (TPA), 20 urokinase, hirudin, and streptokinase, antiproliferatives (methotrexate, cisplatin, fluorouracil, Adriamycin, and the like) antioxidants (ascorbic acid, carotene, B, vitamin E, and the like), antimetabolites, thromboxane inhibitors, non-steroidal 25 and steroidal anti-inflammatory drugs, Beta and Calcium channel blockers, genetic materials including DNA and RNA fragments, and complete expression genes, carbohydrates, and proteins including but not limited to antibodies (monoclonal and polyclonal) lymphokines and 30 growth factors, prostaglandins, and leukotrienes. The stent also incorporates bioactive materials such as fibronectin, laminin, elastin, collagen, and intergrins.

-23-

Fibronectin promotes adherence of the stent to the tissue of the vessel 12.

In one specific example of a biodegradable material incorporating drugs, a poly-L-lactide having an 5 intrinsic viscosity of 2.3 dl/g is used to form monofilament fibers using a spin or melt spinning process. Five percent aspirin or 5% heparin was incorporated into the melt of the poly-L-lactide prior to fiber formation. The fibers formed had a diameter of 10 approximately 0.5 millimeters. The monofilaments were then stretched under temperatures ranging from 50° C to 200° C to orient the fiber. The temperature employed depends upon the kind of material used to make the fiber. The final diameter of the oriented fiber falls 15 within a range of 0.1 to 0.3 millimeters. Similar processing was used to incorporate 5% aspirin or 5% heparin into poly-L-lactide and polyglycolide.

Just as the use of a variety of biodegradable materials facilitates a controlled degradation of the 20 biodegradable stent, so similarly does the incorporation of a variety of drugs into the biodegradable materials facilitate control of drug release to perform a variety of functions. For instance, drugs released from the outer surface as the outer surface degrades facilitate 25 adherence of the stent to the inner surface wall 24 of the vessel 12. Drugs released from fibers perform a variety of functions, ranging from promoting cell growth to altering the blood clotting mechanisms, depending upon from what fiber the drug is released. In one 30 embodiment, drugs released from the inner surface 22 of the stent as the inner surface degrades temper platelet function in blood flowing through the lumen 13.

-24-

The rate of release of drugs promoting cell growth has the capability of increasing the rate of degradation of the biodegradable stent by increasing a rate of resorption. Similarly, the rate of release of drugs promoting cell growth has the capability of decreasing the rate of degradation by decreasing the rate of resorption. The stent of the present invention includes embodiments where drugs are incorporated in a manner that both increases and decreases the rate of degradation of the biodegradable stent over the life of the stent.

Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

-25-

WHAT IS CLAIMED IS:

1. A biodegradable stent for insertion into a lumen of a vessel of a living being, the stent comprising:

a generally tubular biodegradable main body having an exterior surface for contacting the vessel when the main body is placed in the living being and an interior surface contacting a fluid passing through the lumen of the vessel, the tubular main body made from an array of individual biodegradable materials having individual rates of degradation, the individual biodegradable materials incorporating a drug and releasing the drug into the lumen of the vessel at a rate controlled by the rates of degradation of the biodegradable materials.

2. The stent of claim 1 wherein the tubular biodegradable main body includes a plurality of layers made from the array of individual biodegradable materials that degrade at different rates.

3. The stent of claim 1 wherein the biodegradable main body includes a drug that is releasable at a rate that modifies an individual rate of degradation of an individual biodegradable material.

4. The biodegradable stent of claim 1 wherein the plurality of drugs includes bioactive materials such as fibronectin, laminin, elastin, collagen, and intergrins,

-26-

heparin, heparin fragments, aspirin, coumadin, tissue plasminogen activator (TPA), urokinase, hirudin, streptokinase, antiproliferatives methotrexate, cisplatin, fluorouracil, Adriamycin, ascorbic acid, carotene, vitamin B, vitamin E, antimetabolites, thromboxane inhibitors, non-steroidal and steroid anti-inflammatory drugs, Beta and Calcium channel blockers, genetic materials including DNA and RNA fragments, and complete expression genes, carbohydrates, and proteins including but not limited to antibodies, lymphokines, ingrowth factors, prostaglandins, and leukotrienes.

5. A stent for insertion into a lumen of a vessel of a living being, the stent comprising a tubular main body comprising a cambered interior surface contacting a fluid passing through the lumen of the vessel, a leading end facing a direction of flow and a trailing end wherein the main body has substantially the same thickness at the leading as at the trailing end.

6. The stent of claim 5 wherein a camber of the cambered interior surface has an angle of curvature that is substantially within a range of 10° to 20°.

7. The stent of claim 1 wherein the tubular main body has a length and a diameter such that the diameter is at least about two times greater than the length.

8. The biodegradable stent of claim 1 wherein the tubular main body is a coiled strip.

-27-

9. The biodegradable stent of claim 1 wherein the exterior surface includes pores, the pores having a diameter, depth and distribution that are effective to promote growth of cells on the exterior surface.
10. The stent of claim 1 and further including a water soluble coating that overlays the interior surface.
11. The stent of claim 1 wherein the array of biodegradable materials is treated by application of energy of a magnitude ineffective to cause bonding with living tissue of the lumen while the stent is in the lumen.
12. The stent of claim 11 wherein the energy causes an increase in temperature of the array of biodegradable materials above a glass transition temperature of the biodegradable materials.
13. The stent of claim 11 and further including a meltable film coating that overlays the interior surface and that melts upon application of the energy.
14. The stent of claim 1 having a tubular main body that springs out from a radially compressed state to abut a wall of the lumen wherein the tubular main body is treated by application of energy of a magnitude ineffective to cause bonding with the wall of the lumen after the tubular main body abuts the wall of the lumen.
15. The stent of claim 14 wherein the energy is thermal energy that elevates a temperature of the array

-28-

of biodegradable materials of the tubular main body above a glass transition temperature of the array.

16. The stent of claim 15 and further including a melttable film coating that overlays the interior surface of the biodegradable main body and that melts upon application of the thermal energy.

17. The stent of claim 14 wherein the array of biodegradable materials of the tubular main body is treated by application of mechanical energy of a magnitude less than an elastic limit of the array.

18. The stent of claim 17 and further including a plurality of microcapsules within the array of biodegradable materials, the microcapsules containing a material inducing crosslinking of the biodegradable materials wherein the application of energy causes a bursting of the microcapsules and a releasing of the material inducing crosslinking into the biodegradable materials.

19. A method for shaping a tubular main body of a biodegradable stent made of an array of biodegradable materials having a deformable shape comprising:

positioning the array around and about a balloon of a catheter to form the tubular main body with a first diameter;
moving the balloon to a site within a lumen of a vessel of a living being;
expanding the tubular main body by an expansion of the balloon to increase the

-29-

first diameter of the tubular main body to a second diameter; heating the tubular main body to a temperature above a glass transition temperature and below a melting temperature of the biodegradable materials of the array; cooling the tubular main body; and releasing the main body from the balloon.

20. The stent of claim 19 wherein the tubular main body includes a meltable coating that adheres the tubular main body to the balloon until the tubular main body is heated.



21. The stent of claim 19 wherein the tubular main body includes a water soluble coating that adheres the tubular main body to the balloon until the tubular main body is heated.

22. The biodegradable stent of claim 1 wherein the tubular biodegradable main body includes:

a slot extending lengthwise through the main body and defined by opposing edges of the main body wherein the opposing edges are moved toward each other under compression in order to transport the biodegradable stent through a vessel of a living being; and

a plurality of apertures extending through the main body.

1/3



2/3





Fig. 3

3/3



INTERNATIONAL SEARCH REPORT

PCT/US92/08463

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61F 2/06

US CL : 623/1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 623/11, 12; 623/1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	US, A, 5,147,400 (Kaplan et al.) 15 September 1992 See column 4, lines 29-44; column 7, lines 35-62; and column 11, lines 34-50.	1-4, 7, 8, 9, 10, 13
Y	US, A, 4,877,030 (Beck et al.) 31 October 1989 See column 1, lines 5-15 and figure 3.	5, 6, 8, 9, 14
X, P	US, A, 5,078,736 (Behl) 07 January 1992 See whole document.	12, 13, 14, 15, 16, 22

Further documents are listed in the continuation of Box C.

See patent family annex.

•	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

29 NOVEMBER 1992

Date of mailing of the international search report

14 JAN 1993

Name and mailing address of the ISA/
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized office

DEBRA S. BRITTINGHAM

Telephone No. (703) 308-0858